list of antiretroviral fixed-dose combinations list of antiretroviral fixed-dose combinations antiretroviral drugs are used to manage hiv/aids. multiple antiretroviral drugs are often combined into a single pill in order to reduce pill burden. some of these combinations are complete single-tablet regimens; the others must be combined with additional pills to make a treatment regimen. brand name(s) ingredients (inn) food and drug administration (fda) approval date european medicines agency (ema) approval date health canada approval date company single-tablet regimen? nrtis / ntrtis nnrti insti pi pk enhancer combivir lamivudinezidovudine september 26, 1997 viiv healthcare no kaletra (developed countries)aluvia (developing countries) lopinavir ritonavir september 15, 2000 abbott laboratories no trizivir abacavirlamivudinezidovudine november 15, 2000 viiv healthcare yes epzicom (us)kivexa (eu, ru) abacavirlamivudine august 2, 2004 viiv healthcare no generics, e.g., triomune lamivudinestavudine nevirapine (not approved) (many companies) yes generics, e.g., duovir-n lamivudinezidovudine nevirapine (not approved) (many companies) yes truvada emtricitabinetenofovir disoproxil august 2, 2004 gilead sciences no atripla emtricitabinetenofovir disoproxil efavirenz july 12, 2006 gilead sciencesbristol-myers squibb yes complera (us)eviplera (eu, ru) emtricitabinetenofovir disoproxil rilpivirine august 10, 2011 gilead sciencesjanssen pharmaceutica yes stribild emtricitabinetenofovir disoproxil elvitegravir cobicistat august 27, 2012 gilead sciences yes triumeq abacavirlamivudine dolutegravir august 22, 2014 viiv healthcare yes evotaz atazanavir cobicistat january 29, 2015 bristol-myers squibb no prezcobix (us)rezolsta (eu) darunavir cobicistat january 29, 2015 janssen pharmaceutica no dutrebis lamivudine raltegravir february 6, 2015 merck & co. no genvoya emtricitabinetenofovir alafenamide elvitegravir cobicistat november 5, 2015 gilead sciences yes odefsey emtricitabinetenofovir alafenamide rilpivirine march 1, 2016 gilead sciences yes descovy emtricitabinetenofovir alafenamide april 4, 2016 gilead sciences no juluca rilpivirine dolutegravir november 21, 2017 viiv healthcare yes symfi, symfi lo lamivudinetenofovir disoproxil efavirenz february 5, 2018 (symfi lo)march 22, 2018 (symfi) mylan yes biktarvy emtricitabinetenofovir alafenamide bictegravir february 7, 2018 gilead sciences yes cimduo, temixys lamivudinetenofovir disoproxil february 28, 2018 mylan no symtuza emtricitabinetenofovir alafenamide darunavir cobicistat july 17, 2018 janssen pharmaceutica yes delstrigo lamivudinetenofovir disoproxil doravirine august 30, 2018 merck & co. yes dovato lamivudine dolutegravir april 8, 2019 viiv healthcare yes cabenuva rilpivirine cabotegravir january 21, 2021 march 18, 2020 viiv healthcare no